NYSE:GKOS - Glaukos Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $61.31 +1.84 (+3.09 %) (As of 11/16/2018 03:14 PM ET)Previous Close$59.47Today's Range$58.76 - $62.5852-Week Range$23.08 - $70.91Volume25,962 shsAverage Volume468,535 shsMarket Capitalization$1.98 billionP/E RatioN/ADividend YieldN/ABeta1.53 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. The company markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation has a collaboration agreement with D. Western Therapeutics Institute for the development of novel intraocular products for the treatment of glaucoma. The company was founded in 1998 and is headquartered in San Clemente, California. Receive GKOS News and Ratings via Email Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:GKOS Previous Symbol CUSIPN/A Webwww.glaukos.com Phone949-367-9600 Debt Debt-to-Equity RatioN/A Current Ratio7.07 Quick Ratio6.53 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$159.25 million Price / Sales13.44 Cash Flow$0.1692 per share Price / Cash362.27 Book Value$4.68 per share Price / Book13.10 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-90,000.00 Net Margins-8.13% Return on Equity-9.26% Return on Assets-7.95% Miscellaneous Employees387 Outstanding Shares34,910,000Market Cap$1.98 billion OptionableOptionable Glaukos (NYSE:GKOS) Frequently Asked Questions What is Glaukos' stock symbol? Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS." How were Glaukos' earnings last quarter? Glaukos Corp (NYSE:GKOS) announced its earnings results on Wednesday, November, 7th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.05. The medical instruments supplier had revenue of $43.91 million for the quarter, compared to analyst estimates of $41.65 million. Glaukos had a negative return on equity of 9.26% and a negative net margin of 8.13%. The company's quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.04 earnings per share. View Glaukos' Earnings History. When is Glaukos' next earnings date? Glaukos is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Glaukos. What price target have analysts set for GKOS? 10 brokerages have issued 12-month target prices for Glaukos' stock. Their forecasts range from $35.00 to $75.00. On average, they anticipate Glaukos' stock price to reach $59.7778 in the next year. This suggests that the stock has a possible downside of 2.5%. View Analyst Price Targets for Glaukos. What is the consensus analysts' recommendation for Glaukos? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Glaukos. Has Glaukos been receiving favorable news coverage? Media headlines about GKOS stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Glaukos earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. Who are some of Glaukos' key competitors? Some companies that are related to Glaukos include Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD), Penumbra (PEN), ICU Medical (ICUI), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR) and Atrion (ATRI). Who are Glaukos' key executives? Glaukos' management team includes the folowing people: Mr. Thomas William Burns, CEO, Pres & Director (Age 57)Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 42)Mr. Chris M. Calcaterra, COO & Chief Commercial Officer (Age 58)Mr. Richard L. Harrison, Advisor (Age 61)Dr. Mory Gharib Ph.D., Co-Founder When did Glaukos IPO? (GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. Who are Glaukos' major shareholders? Glaukos' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (8.99%), Capital World Investors (8.08%), William Blair Investment Management LLC (7.00%), BlackRock Inc. (6.91%), Baillie Gifford & Co. (3.87%) and Gilder Gagnon Howe & Co. LLC (3.67%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos. Which major investors are selling Glaukos stock? GKOS stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Interwest Venture Management Co., Peregrine Capital Management LLC, Jennison Associates LLC, William Blair Investment Management LLC, Rhenman & Partners Asset Management AB, Wells Fargo & Company MN and Deutsche Bank AG. Company insiders that have sold Glaukos company stock in the last year include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Orbimed Advisors Llc, Thomas William Burns and William J Phd Link. View Insider Buying and Selling for Glaukos. Which major investors are buying Glaukos stock? GKOS stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Baillie Gifford & Co., Point72 Asset Management L.P., Engineers Gate Manager LP, First Trust Advisors LP, Primecap Management Co. CA, JPMorgan Chase & Co. and JPMorgan Chase & Co.. View Insider Buying and Selling for Glaukos. How do I buy shares of Glaukos? Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Glaukos' stock price today? One share of GKOS stock can currently be purchased for approximately $61.31. How big of a company is Glaukos? Glaukos has a market capitalization of $1.98 billion and generates $159.25 million in revenue each year. Glaukos employs 387 workers across the globe. What is Glaukos' official website? The official website for Glaukos is http://www.glaukos.com. How can I contact Glaukos? Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected] MarketBeat Community Rating for Glaukos (NYSE GKOS)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 298 (Vote Outperform)Underperform Votes: 197 (Vote Underperform)Total Votes: 495MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/16/2018 by MarketBeat.com StaffFeatured Article: Why do companies engage in swaps?